Did you know?

The IWMF raised more than five million dollars for WM medical research

Did you know?

The IWMF raised more than 60 support groups in North America and nearly 20 others world-wide

Did you know?

The IWMF has a current worldwide membership of nearly 4,000

Did you know?

IWMF-TALK is a wonderful place to share information and learn from other survivors

Did you know?

Each year 1,500 new cases of Waldenstrom's macroglobulinemia are diagnosed in the USA

Did you know?

Volunteers at the IWMF Telephone Lifeline are waiting to share their experiences with you

Did you know?

You can order DVD recordings of past WM Educational Forums online or by mail

Did you know?

All IWMF programs and services are funded by WM survivors, caregivers, friends, and family

IWMF News and Events

  • Historic Day for WMers - US FDA Approves Imbruvica (Ibrutinib) for WM

    1.29.2015 - 3.31.2015


    In a history-making moment for WM patients, the IWMF is pleased to announce that Imbruvica (ibrutinib) has just received FDA approval specifically for the treatment of WM, thus becoming the first drug therapy to achieve this designation. 


    Imbruvica, developed jointly by Pharmacyclics and Janssen Biotech Inc., previously received "Breakthrough Therapy Designation" for WM. This expedited its development and review, and Imbruvica had already been approved for patients with chronic lymphocytic leukemia and mantle cell lymphoma.  With this new approval and specific designation for use in WM, physicians can now prescribe Imbruvica for all WM patients and many of these patients will be able to obtain better insurance coverage for its cost.


    There are many other drugs "in the pipeline," both oral and injectable.  Imbruvica is an oral inhibitor of Bruton's tyrosine kinase (BTK) and blocks signals that stimulate malignant B-cells to grow and divide uncontrollably.  Pharmaceutical companies are developing treatments that target this and other signaling pathways to provide additional therapy options.  As IWMF President Carl Harrington says, "We are thrilled that the scientific and drug development communities are paying attention to Waldenstrom's macroglobulinemia. Rather than receiving treatments that have been developed for other B-cell lymphomas, we are now getting testing and recognition that are specific to our disease."


    Pharmacyclics also recently announced that the European Medicines Agency (EMA) has accepted its application for Imbruvica to treat WM patients in Europe.  If the application is approved, Imbruvica will also be the first drug specifically authorized for WM in Europe.


    While this is certainly a cause for celebration, Imbruvica is not a cure and not every WM patient responds to it.  The search continues for curative therapies, and it is important for the IWMF to continue to fund research toward this ultimate goal.  We hope that you will join with us, not only in applauding this achievement, but also in working toward a cure for WM.


    For more information about this exciting news please see the following press releases from Pharmacylics, Janssen Biotech, Inc., and the FDA. 



    The IWMF Board of Trustees



  • 2015 IWMF Ed Forum

    5.1.2015 - 5.3.2015

    Plan now to attend the 20th IWMF Patient Education Forum.  Click: Details/Information to find out more about it.


    The event is an opportunity to hear about the latest research and treatments from WM experts, meet fellow patients and caregivers, renew old friendships, and welcome our newest members.


    See y'all in Dallas, pardners!

  • Upcoming IWMF Support Group Meetings

    9.29.2014 - 9.27.2015

    All meetings worldwide, click HERE

  • Upcoming WM-Related Conferences & Events

    9.29.2014 - 9.27.2015

    All events worldwide, CLICK HERE